Latest News for: 2510
Edit
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Nasdaq Globe Newswire 06 Jan 2026
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco ... .
Edit
Hastings Tribune
06 Jan 2026
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License
(“Axion”), a wholly-owned subsidiary of Instil, has ...
- 1